Peter is a current Director and the inaugural and Past-Chair of Linear Clinical Research (Linear), a wholly owned subsidiary of the Harry Perkins Institute of Medical Research (Perkins), and has been involved with Linear since its inception. He is the Chief Executive Officer and Director of the Perkins and a Professor of Medicine at University of Western Australia (UWA).
He graduated in medicine from UWA then undertook specialist training in endocrinology at Royal Melbourne Hospital in the 90s. He completed PhD studies at the Walter and Eliza Hall Institute of Medical Research and postdoctoral studies at Harvard Medical School, before returning to Perth.
Peter is internationally recognised for his RNA-based research on hormone-dependent cancers (breast and prostate) and more lately on poor prognostic tumours (liver and head and neck cancer). As Laboratory Head of Cancer Medicine at the Perkins Institute, he and his team are developing microRNA-based therapies for these solid tumours that are being translated towards the bedside.
Peter is a Board Member of the national Association of Australian Medical Research Institutes, Fellow of the Australian Academy of Health and Medical Sciences, a Graduate of the Australian Institute of Company Directors and co-founder of miReven, a biotech company focused on developing a novel way to treat liver cancer with micro RNAs. Peter was appointed an Officer of the Order of Australia in the Australia Day 2021 Honours List for distinguished service to medicine, health and medical research as a physician scientist, to professional societies, and to tertiary education.
Michael is currently CEO and Managing Director of Emyria, a listed biotech company leveraging Real World Data to accelerate the delivery and development of new treatments for mental healthcare and select neurological conditions. Previously, Michael served as the CEO of Linear from April 2016 to October 2019.
Under Michael’s leadership, Linear expanded its cancer trial team and was the first site in Australia to adopt electronic source data capture. This contributed to a period of rapid growth with clientele from the USA, Europe, Japan and China.Prior to Linear, Michael was based in Silicon Valley as the health lead for Palantir Technologies where he led deployments for health companies and government organisations across the US and UK.Michael has a Master of Business Administration from Stanford University and a Bachelor of Medicine, Bachelor of Surgery Degree from the University of Western Australia.
Mark has held senior executive and board positions, in start-ups and listed and unlisted entities in Australia and the USA, over a 30-year career. Most recently Mark was the worldwide CTO and VP for Corporate Strategy at Hewlett Packard Enterprise.
Prior to Hewlett Packard, Mark was the founder of several successful, venture-backed start-ups that have driven technology disruption and business innovation in varied industries. Mark has also served as a non-executive director at Resolute Mining Limited (ASX:RSG appointed 2017), iCetana (ASX:ICE appointed 2018), as non-executive chairman of Decimal Software (ASX:DSX) and is currently a non-executive director at Land Services WA, and Land Services SA.
In her 3 decade career as non-executive director, Fiona has gained experience in many sectors, including Energy and Resources, Utilities, Financial Services and Property. She has been a Chairman, Lead Independent Director and Director of approximately 30 companies in the public, private, not for profit and government sectors. Previously Fiona was a partner with KPMG, working with the firm in Perth, San Francisco & Sydney.
Fiona’s leadership in the WA director community saw her elected as State President of the Australian Institute of Company Directors in 2005 - the first woman to hold this position. Her contribution to the economic progress of WA and to the highest standards of corporate governance was recognised in 2016 when she was awarded the AICD WA Gold Medal and in 2021 when she was made a Member of the Order of Australia (AM) for significant service to the finance, investment, resources and not-for-profit sectors.
Nina has over thirty years of experience in the pharmaceutical industry, with leadership roles in investor relations, business development, and prosecution of intellectual property matters, as well as leading and managing the strategic, scientific and operational aspects of pharmaceutical product development.
Nina is currently the CEO & Managing Director for Dimerix Limited (ASX:DXB), an Australian drug pharmaceutical company focussed on developing products in inflammatory diseases through clinical trials, licensing and commercialisation. Nina was formerly the Commercial Director for Acrux Limited (ASX:ACR), where she has successfully developed and commercialised multiple products globally. Prior to Acrux, Nina was Director of commercialisation and Intellectual Property for Immuron Limited (ASX:IMC), and previously spent 6 years in new product development with Wyeth Pharmaceuticals in the UK (now part of Pfizer). Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT. Nina is also the Non-executive Chair of SYNthesis BioVentures Pty Ltd.
Roger is currently the chair of Linear Clinical Research Limited and a non-executive director of CTI Logistics Limited (ASX:CLX), Eagle Mountain Mining Limited (ASX:EM2) and Cullen Wines (Australia) Pty Ltd. He has held a number of non-executive director roles over the past 25 years including in the health and medical research, aged care and education sectors, including as a board member of the Harry Perkins Institute of Medical Research from 2015 to 2024.
Roger was a partner of PricewaterhouseCoopers for 19 years up to his retirement from the firm in 2016. He has extensive experience in financial analysis, company and business valuations, transaction due diligence and mergers and acquisitions across a range of industries and led the PwC Perth Deals team for seven years.
He is a graduate of Macquarie University and a Fellow of Chartered Accountants Australia and New Zealand, a Fellow of the Australian Institute of Company Directors and a former Senior Fellow of the Financial Services Institute of Australasia.
Andy is Consultant Medical Oncologist at Fiona Stanley Hospital, a translational cancer researcher with the University of Western Australia, and current clinical head of the Cancer Division at Harry Perkins Institute. He has active research projects in breast cancer, prostate cancer, melanoma and bowel cancer, with a focus on growth signalling and mechanisms of chemotherapy and hormone therapy resistance in cancer.
In addition to conducting a variety of human trials of chemotherapies, hormone therapies and immune therapies, Andy also co-ordinates training for advanced medical oncology doctors in WA, and is the State Lead Clinical for breast cancer overseeing services.
Chinese
Australian